COMMUNIQUÉS West-GlobeNewswire

Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®

17/09/2024 - 13:00

MELBOURNE, Australia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as a [...]

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

17/09/2024 - 13:00

Two patients dosed; several additional patients screened for enrollment Trial to evaluate safety and tolerability of TTX-MC138 in patients with metastatic cancer TTX-MC138 is an antisense oligonucleotide conjugated to [...]

AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease

17/09/2024 - 13:00

AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease Prescreening rate of Phase 2b ReTain trial triggers clinical development milestone [...]

BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024

17/09/2024 - 12:45

MAINZ, Germany, September 17, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”), alongside its artificial intelligence (“AI”) company InstaDeep Ltd. (“InstaDeep”), will host an AI Day, an edition of [...]

ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.

17/09/2024 - 12:30

Strategic Rebranding Reflects Focus on Neurodegenerative Therapies and Healthy Longevity NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The Board of ANEW MEDICAL, INC. (NASDAQ: WENA), today announced a name and ticker [...]

De nouvelles données de l’étude SunRISe-1 de la Phase 2b portant sur le TAR-200 montrent un taux de réponse complète de 84 pour cent chez les patients atteints d’un cancer de la vessie non invasif sur le plan musculaire à haut risque

17/09/2024 - 11:08

La monothérapie expérimentale TAR-200 démontre un taux de réponse complète élevé sans besoin de réinduction ou de traitement adjuvant chez les patients ne répondant pas au bacille de Calmette-Guérin (BCG) 1 BEERSE, [...]

KFSHRC Drives Saudi Arabia’s Rise as Global Biotech Powerhouse

17/09/2024 - 10:29

RIYADH, Saudi Arabia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is leading Saudi Arabia’s efforts to become a global biotechnology powerhouse by pioneering [...]

IMU Biosciences expands leadership team with appointment of industry experts Dr. John Baker as Chief Executive Officer and Dr. Jason Brown as Chief Business Officer

17/09/2024 - 08:00

IMU Biosciences expands leadership team with appointment of industry experts Dr. John Baker as Chief Executive Officer and Dr. Jason Brown as Chief Business Officer London, UK, 17 September 2024 – IMU Biosciences (or “ [...]

SAFE - Prise d’effet des opérations de regroupement et première cotation des actions nouvelles regroupées

17/09/2024 - 08:00

Prise d’effet des opérations de regroupement et première cotation des actions nouvelles regroupées • Réalisation du regroupement des actions • Début des négociations des actions nouvelles issues du regroupement le 18 [...]

EssilorLuxottica and Meta Announce Long Term Partnership, Shaping the Future of the Smart Eyewear Category

17/09/2024 - 07:34

EssilorLuxottica and Meta Announce Long Term Partnership, Shaping the Future of the Smart Eyewear Category Building on the success of Ray-Ban Meta glasses, the two pioneering companies aim to write history of wearables [...]

EssilorLuxottica et Meta annoncent un partenariat de long terme structurant le futur des lunettes intelligentes

17/09/2024 - 07:34

EssilorLuxottica et Meta annoncent un partenariat de long terme structurant le futur des lunettes intelligentes Forts du succès des lunettes Ray-Ban Meta, les deux pionniers visent à écrire ensemble le destin des [...]

Véronique Pomi-Schneiter stands down as BioSenic's Deputy CEO

17/09/2024 - 07:00

PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, September 17, 2024 7.00pm CEST – BioSenic (Euronext Brussels and Paris: BIOS) , the clinical stage company specializing in serious autoimmune and inflammatory diseases [...]

Véronique Pomi-Schneiter démissionne de ses fonctions de Directrice Générale Adjointe de BioSenic

17/09/2024 - 07:00

INFORMATION PRIVILIGIEE Mont-Saint-Guibert, Belgique, le 17 septembre 2024, 7h00 CEST – BIOSENIC (Euronext Bruxelles et Paris : BIOS), la société en phase clinique spécialisée dans les maladies auto-immunes et [...]

UPDATE – Leading PACE Provider InnovAge Selected to Participate in National Study Focused on Preventing Falls by Seniors

17/09/2024 - 00:19

New LeaHD Study Advances as Industry Observes National PACE Awareness Month & Falls Prevention Month DENVER, Sept. 16, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by InnovAge [...]

Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy

16/09/2024 - 22:06

Innovative drug treatment developed in collaboration with SciSparc aims to enhance safety and efficacy in mental health and addiction care Vancouver, Canada, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ( [...]

SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy

16/09/2024 - 22:06

This innovative drug combination treatment focuses on boosting safety and efficacy in mental health and addiction care TEL AVIV, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or " [...]

MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

16/09/2024 - 22:05

CARMEL, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide [...]

89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer

16/09/2024 - 22:05

SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of [...]

Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference

16/09/2024 - 22:05

REDWOOD CITY, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, [...]